Literature DB >> 8439502

Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression.

K A Saraya1, F R Balkwill.   

Abstract

A study of activation of the cytokine network by interleukin 2, IL-2, may provide a rationale for devising cytokine combination and cytokine antagonist treatments with increased anti-tumour efficacy and decreased toxicity. We have investigated the expression of mRNA for 13 cytokines and three transcription factors during in vitro culture of peripheral blood mononuclear cells, PBMC, with IL-2. A consistent pattern of induction was seen in nine individuals, with early (2-24 h) induction of IL-1 beta, IL-6, tumour necrosis factor, TNF, lymphotoxin, LT, and gro. TNF and LT mRNA was expressed continually throughout culture, but levels of mRNA for IL-1 beta, IL-6, and gro declined by 24-48 h. After 48 h, PBMC began to express mRNA for IFN-gamma, IL-5, GM-CSF, and M-CSF. At 15 min to 1 h post IL-2 mRNA for c-fos, c-jun, and c-myc, and TNF was induced in three individuals studied. IL-4, IFN-alpha, and IL-1 alpha mRNA was not detected. Only a minority of cells expressed mRNA for TNF, IL-1 beta, IL-6 and IFN-gamma, and monocytes were the main source. Levels of cytokine protein in culture supernatants mirrored the pattern of mRNA induction. This in vitro model shows clear parallels with the reported in vivo production of cytokines during IL-2 therapy, and may prove useful in designing new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439502      PMCID: PMC1968251          DOI: 10.1038/bjc.1993.96

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.

Authors:  E J Kovacs; S K Beckner; D L Longo; L Varesio; H A Young
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

Review 2.  Molecular biology of cell activation.

Authors:  L Kaczmarek; B Kamińska
Journal:  Exp Cell Res       Date:  1989-07       Impact factor: 3.905

3.  Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

Authors:  A Kasid; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

4.  Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

Authors:  A Belldegrun; A Kasid; M Uppenkamp; S L Topalian; S A Rosenberg
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

5.  Antimitogenic and mitogenic actions of interleukin-1 in diverse cell types are associated with induction of gro gene expression.

Authors:  V V Rangnekar; S Waheed; T J Davies; F G Toback; V M Rangnekar
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

6.  IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells.

Authors:  R P Numerof; F R Aronson; J W Mier
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

7.  Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1.

Authors:  E V Gaffney; S C Tsai
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

Authors:  J P Dutcher; S Creekmore; G R Weiss; K Margolin; A B Markowitz; M Roper; D Parkinson; N Ciobanu; R I Fisher; D H Boldt
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

9.  Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.

Authors:  T Aoki; H Kikuchi; S Miyatake; Y Oda; K Iwasaki; T Yamasaki; T Kinashi; T Honjo
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

Authors:  D L Fraker; H N Langstein; J A Norton
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  4 in total

1.  Circulating pro-inflammatory cytokines are elevated and peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient adults.

Authors:  Tyler Barker; Thomas B Martins; Harry R Hill; Carl R Kjeldsberg; Brian M Dixon; Erik D Schneider; Vanessa T Henriksen; Lindell K Weaver
Journal:  Eur J Appl Physiol       Date:  2013-01-06       Impact factor: 3.078

2.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

3.  Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

Authors:  D J Deehan; S D Heys; W Simpson; R Herriot; J Broom; O Eremin
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

4.  The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.

Authors:  Dominique Musselman; Erica B Royster; Ming Wang; Qi Long; Lisa M Trimble; Tara K Mann; Daniel S Graciaa; Marcia D McNutt; N S Freda Auyeung; Lindsay Oliver; David H Lawson; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2013-04-10       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.